Showing 1 - 10 of 104
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10014080046
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D investments...
Persistent link: https://www.econbiz.de/10012833741
to fight the disease. However, high vaccine prices enforced through patent protection are limiting vaccine expansion …, particularly in low- and middle-income countries. By limiting market power, patent buyouts could reduce vaccine prices and raise … HPV vaccination rates while keeping innovation incentives. We estimate the global patent buyout price as the present …
Persistent link: https://www.econbiz.de/10012825394
experiment from Norway, which in 2003 introduced a reference price (RP) system called "index pricing" for a sub-sample of off-patent … pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel … regulation in lowering drug prices, while the cross-price effect raises a concern about patent protection …
Persistent link: https://www.econbiz.de/10013316907
Ohio announced a Vax-a-Million Lottery in May 2021 to encourage people vaccinated. If people may avoid vaccination because (1) they worry about rare but critical side effects or (2) they want to free ride on herd immunity, the vaccination lottery may work better or worse than a lump-sum transfer...
Persistent link: https://www.econbiz.de/10013216770
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012843430
This paper provides insights into the determinants of bargaining power and how they affect drug prices. Our data show that drug prices vary across buyers and time periods. We estimate a structural bargaining model where drug suppliers and buyers engage in bilateral bargaining over drug prices....
Persistent link: https://www.econbiz.de/10012845687
pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear … regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers …
Persistent link: https://www.econbiz.de/10012860771
patent application. The analysis is based on patent data from the Norwegian Industrial Property Office merged with data from … for confounding factors. The first patent application by a young firm is associated with significant growth in employment … three years ahead of the first patent application. However, we find no evidence of additional firm growth after patent …
Persistent link: https://www.econbiz.de/10014077007
Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...
Persistent link: https://www.econbiz.de/10010274736